BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
Portfolio Pulse from Vandana Singh
The FDA has approved BioMarin Pharmaceutical Inc's Roctavian gene therapy for adults with severe hemophilia A. The company's focus now shifts to its US commercial strategy, following failed attempts to launch in the EU. BioMarin plans to offer an outcomes-based warranty to all payers, ensuring reimbursements up to 100% if the patient does not respond. The company estimates that commercial Roctavian will be available in about 2 months. Analysts maintain a Neutral and Market Perform rating on BioMarin, with a raised price target from $69 to $73.
June 30, 2023 | 6:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioMarin's Roctavian has received FDA approval, shifting the company's focus to its US commercial strategy. Analysts maintain a Neutral and Market Perform rating on the company, with a raised price target.
The FDA approval of Roctavian is a significant milestone for BioMarin. However, the company's failed attempts to launch in the EU and the uncertainty surrounding its US commercial strategy may impact investor sentiment. The raised price target by analysts indicates a positive outlook, but the Neutral and Market Perform ratings suggest caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100